StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Castle Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$12.08M, down 254.3% year over year. For fiscal 2025 it was -$2.04M, down 108.3% from the year before. The highest annual figure on record is $24.67M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.04M-108.3%
FY2024Dec 31, 2024$24.67M–
FY2023Dec 31, 2023-$55.65M–
FY2022Dec 31, 2022-$62.31M–
FY2021Dec 31, 2021-$36.67M–
FY2020Dec 31, 2020-$6.07M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.45M–
Q2 FY2026Jun 30, 2026$1.00M–
Q1 FY2026Mar 31, 2026-$14.48M-888.6%
Q4 FY2025Dec 31, 2025-$50.00K-100.5%
Q3 FY2025Sep 30, 2025-$2.99M-134.7%
Q2 FY2025Jun 30, 2025-$837.00K-110.0%
Q1 FY2025Mar 31, 2025$1.84M–
Q4 FY2024Dec 31, 2024$9.82M–
Q3 FY2024Sep 30, 2024$8.62M–
Q2 FY2024Jun 30, 2024$8.36M–
Q1 FY2024Mar 31, 2024-$2.13M–
Q4 FY2023Dec 31, 2023-$2.43M–
Q3 FY2023Sep 30, 2023-$6.47M–
Q2 FY2023Jun 30, 2023-$18.12M–
Q1 FY2023Mar 31, 2023-$28.63M–
Q4 FY2022Dec 31, 2022-$19.99M–
Q3 FY2022Sep 30, 2022-$18.61M–
Q2 FY2022Jun 30, 2022-$1.34M–
Q1 FY2022Mar 31, 2022-$22.37M–
Q4 FY2021Dec 31, 2021-$13.72M–
Q3 FY2021Sep 30, 2021-$10.73M–
Q2 FY2021Jun 30, 2021-$8.18M–
Q1 FY2021Mar 31, 2021-$4.05M–
Q4 FY2020Dec 31, 2020-$2.87M–
Q3 FY2020Sep 30, 2020-$3.78M–

More Castle Biosciences figures

See a number that looks wrong?